Clinical and laboratory observationSeasonal Variation of Maternally Derived Respiratory Syncytial Virus Antibodies and Association with Infant Hospitalizations for Respiratory Syncytial Virus
Section snippets
Material
We used cord blood samples from the Danish National Birth Cohort in combination with data from the RSV database on RSV hospitalizations in the Danish infant population.
Results
Two serum samples had insufficient quantity for the analysis and were excluded. The geometric mean titer of maternally derived RSV-neutralizing antibody in 457 cord blood samples was 7.89 to the log base 2 (percentiles 10% 6; 25% 7; 50% 8; 75% 9; 90% 10).
A temporal correlation between the incidence of RSV hospitalization and the mean RSV antibody titer in cord blood samples was observed (P = .00, correlation coefficient = −0.25) (Figure). Incidence of RSV hospitalization increased when cord RSV
Discussion
This study offered a unique possibility to examine the association between the maternally derived RSV-neutralizing antibody titer in consecutively sampled cord blood and RSV seasonality measured as the weekly RSV hospitalization incidence among Danish infants below 6 months of age. For antibody detection we used an assay that specifically detected neutralizing antibodies and identified titer values similar to the values of an earlier study.10 We found a clear association between the maternally
References (10)
- et al.
Respiratory syncytial virus-specific immunoglobulins in preterm infants
J Pediatr
(1993) - et al.
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies
Vaccine
(2003) - et al.
Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique
J Med Virol
(2002) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group
Pediatrics
(1998)- et al.
Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children
J Infect Dis
(1990)
Cited by (75)
Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study
2023, The Lancet Child and Adolescent HealthGroup B Streptococcus Meningitis in an Infant with Respiratory Syncytial Virus Detection
2020, Journal of PediatricsCitation Excerpt :Nonspecific symptoms are typically more common in neonates aged <3 weeks, and respiratory symptoms are typically present in infants aged >3 weeks.14 It is also important to recognize that although infants aged 1-2 months are the most vulnerable to severe RSV disease,14-16 infants at this age may have milder disease than might be expected due to the presence of RSV-specific maternal antibodies,17-20 which rapidly wane over the first 6 months of life.17,21,22 Given these considerations, it would be difficult for clinicians to credit nonspecific symptoms in febrile infants aged 1-2 months to RSV without careful exclusion of serious bacterial infection.
Survival of recombinant monoclonal and naturally-occurring human milk immunoglobulins A and G specific to respiratory syncytial virus F protein across simulated human infant gastrointestinal digestion
2020, Journal of Functional FoodsCitation Excerpt :Ninety-seven percent of infants have RSV-specific maternal antibodies in their blood at birth (Ochola et al., 2009). Infants with high transplacental RSV-neutralizing antibody concentrations were less susceptible to RSV infection (Stensballe et al., 2009). Human milk contains RSV-specific IgG, IgA and sIgA that can neutralize RSV (Mazur et al., 2019).
Conflict of interest and funding information available in the Appendix (available at www.jpeds.com).